Systemic necrotizing vasculitides: Classifications and therapeutic strategies;Les vascularites nécrosantes systémiques: Classification et stratégies actuelles de traitement

Revue de Medecine Interne

Volumn 24, Issue 3, 2003, Pages 172-182

  Guillevin, L ^a   Mahr, A ^a   Cohen, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Classification criteria; Necrotizing vasculitis; Treatment

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

DISEASE CLASSIFICATION; DISEASE SEVERITY; EUROPE; FRANCE; NECROTIZING ARTERITIS; PATHOGENESIS; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 0037346064     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00815-9     Document Type: Review

References (65)

1. Lightfoot RW, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-93.
2. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100.
3. Leavitt R, Fauci A, Bloch D, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33: 1101-7.
4. Jennette JC, Falk RJ, Andrassy K. Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides, Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
5. Fauci A, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978;89:660-76.
6. Généreau T, Lortholary O, Pottier MA, Michon Pasturel U, Ponge T, de Wazières B, et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis, French Vasculitis Study Group. Arthritis Rheum 1999;42:2674-81.
7. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile cutaneo-mucous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
8. Kallenberg CG, Tervaert JW. What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implicalions. Curr Opin Nephrol Hypertens 1999;8:307-15.
9. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P, Churg-Strauss syndrome, Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
10. Guillevin L, Durand Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
11. Hunder GG, Arend WR Bloch DA, Calabrese LH, Fauci AS, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis, Introduction. Arthritis Rheum 1990;33:1065-7.
12. Watts RA, Scott DG. Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol 1997;11:191-217.
13. Nordborg E. Epidemiology of biopsy-positive giant cell arteritis: an overview. Clin Exp Rheumatol 2000:1(4 Suppl. 20):S15-7.
14. Barrier J, Pion P, Massari R, Peltier P, Rojouan J, Grolleau JY. Approche épidémiologique de la maladie de Horton dans le département de Loire-Atlantique, 110 cas en 10 ans (1970-1979). Rev Med Interne 1982;3:13-20.
15. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis. and rheumatoid arthritis. Arthritis Rheum 1994;37:514-20.
16. Gonzalez-Gay MA, Alonso MD, Aguero JJ, Bal M, Fernandez-Camblor B, Sanchez-Andrade A. Giant cell arteritis in Mediterranean countries: comment on the article by Salvarani et al. Arthritis Rheum 1992;35:1249-50.
17. Yanagawa H, Nakamura Y. Yashiro M, Oki I, Hirata S, Zhang T, et al. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan (abstract). Pediatrics 2001;107:E33.
18. Laupland KB, Dele Davies H. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol 1999;20:177-83.
19. Davis RL, Waller PL, Mueller BA, Dykewicz CA, Schonberger LB. Kawasaki syndrome in Washington State, Race-specific incidence rates and residential proximity to water. Arch Pediatr Adolesc Med 1995;149:66-9.
20. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalence of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome in a French urban population in 2000: a capture-recapture estimate (abstract). Cleve Clin J Med 2002;69(Suppl. 2):170-1.
21. Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001;60:170-2.
22. Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DG. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996;39:1208-12.
23. Lie J. Nomenclature and classification of vasculitis: plus ça change, plus c'est la même chose. Arthritis Rheum 1994;37:181-6.
24. Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol 1995;7:20-4.
25. Trépo C, Thivolet J. Antigen Australia, hépatite à virus et périartérite noueuse. Presse Méd 1970;78:1575.
26. Gocke DJ, Hsu K, Morgan C. Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet 1970;2:1149-53.
27. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinernia. N Engl J Med 1992;327:1490-5.
28. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-9.
29. Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B 19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999;42:1255-8.
30. Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B19. Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology 2002;41:445-9.
31. Duhaut P, Bosshard S, Calvet A, Pinede L, Demolombe-Rague S, Dumontet C, et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study, Groupe de Recherche sur l'Artérite à Cellules Géantes. J Rheumatol 1999;26:361-9.
32. Eden A, Mahr A, Servant A, Radjef N, Amard S, Mouthon L, et al. Lack of association between B19 or V9 Erythrovirus infection and ANCA-positive vasculitides: a case-control study. Rheumatologie 2003, sous presse.
33. Patriarca PA, Rogers MF. Morens DM, Schonberger LB, Kaminski RM, Burns JC, et al. Kawasaki syndrome: association with the application of rug shampoo. Lancet 1982;2:578-80.
34. Klein BS, Rogers MF, Patrican LA, White MC, Burgdorfer W, Schell WL, et al. Kawasaki syndrome: a controlled study of an outbreak in Wisconsin. Am J Epidemiol 1986;124:306-16.
35. Nuyts GD, Van Vlem E, De Vos A, Daelemans RA, Rorive G, Elseviers MM, et al. Wegener granulomatosis is associated to exposure to silicon compounds: a case-control study. Nephrol Dial Transplant 1995;10:1162-5.
36. Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001;12:134-42.
37. Gregorini G, Ferioli A, Donato F, Tira P, Morassi L, Tardanico R, et al. Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study. Adv Exp Med Biol 1993;336:435-40.
38. Lauérière L, Buchler M, El Ghoul Z, Lasfargues G, Lebranchu Y, Fourquet F, et al. Vascularite à ANCA et exposition professionnelle: une étude cas-témoin (abstract). Rev Méd Interne 2002;23(Suppl. 1):69.
39. Duna GF, Cotch MF, Galperin C, Hoffman DB, Hoffman GS. Wegener's granulomatosis: role of environmental exposures. Clin Exp Rheumatol 1998;16:669-74.
40. Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome, A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne 1992;143:405-16.
41. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome, A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
42. Luqmani R, Exley A, Kitas G, Bacon P. Disease assessment and management of the vasculitides. Clin Rheumatol 1997;11:423-46.
43. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients, French Vasculitis Study Group. Arthritis Rheum 2001;44:666-75.
44. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
45. Hoffman G. Treatment of Wegener's granulomatosis: time to change the standard care. Arthritis Rheum 1997;40:2099-104.
46. Luqmani R, Jayne D, EUVAS. A multicenter randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis (CYCAZAREM) (abstract). Arthritis Rheum 1999;42:S225.
47. Guillevin L, Le Clerc P, Jarrousse B, Cohen P, Lhote F, Cordier J, et al. Treatment of severe Wegener's granulomatosis: a prospective trial in 58 patients comparing prednisone, pulse cyclophosphamide versus prednisone and oral cyclophosphamide (abstract). Arthritis Rheum 1994;37:S352.
48. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9.
49. Guillevin I, Cohen P, Mahr A, Arene J, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
50. Newburger J, Takahashi M, Bums J, Bastian J, Chung KJ, Colan SD, et al. Kawasaki syndrome with intravenous gammaglobulins. N Engl J Med 1986;315:341-7.
51. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993;6:207-19.
52. Langford C, Talar-Williams C, Barron K, Sneller K. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remisison maintenance. Arthritis Rheum 1999; 42:2666-73.
53. Clarke AE, Bitton A, Eappen R, Danoff DS, Esdaile JM. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation 1990;50:1047-51.
54. Nowak R, Birck R, Van Der Woude F. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1998;349:754.
55. Metzler C, Löw-Friedriech I, Reinhold-Keller E, Schmitt W, Gross W. Leflunomide, a new promising agent in maintenance of remission in Wegener's granulomatosis (abstract). Clin Exp Immunol 1998;112:S154.
56. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C. Efficacy of anti-TNF antibody infliximab against refractory systemic vasculitides. An open pilot study on 10 patients. Rheumatology 2002;41:1126-32.
57. Pusey C, Rees A, Evans D, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757-63.
58. Guillevin L, Cevallos R, Durand Gasselin B, Lhote F, Jarrousse B, Callard P. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome, Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne 1997;148:198-204.
59. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus, A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995;74:238-53.
60. Cacoub P, Maisonobe T, Thibault V, Gatel A, Servan J, Musset L, et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001;28:109-18.
61. Rieu V, Cohen P, André M, Mouthon L, Godmer P, Jarrousse B, et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology 2002;41:290-300.
62. Cacoub P, Lidove O, Hausfater P, Maisonobe T, Thibault V, Fea C. Antiviral treatment and outcome in patients with hepatitis C virus systemic vasculitis (abstract). Arthritis Rheum 2001;44:S56.
63. Jarrousse B, Guillevin L, Bindi P, Hachulla E, Leclerc P, Nilson B, et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993;11:615-21.
64. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21:246-51.
65. Exley A, Carruthers D, Luqmani R, Kitas G, Gordon C, Janssen B, et al. Damage occurs early in systemic vasculitis and is an index of outcome. Q J Med 1997;90:391-9.